Maraviroc 150Â mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study
Keywords: Antiretroviral therapy; human immunodeficiency virus; maraviroc; naive patients; nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen;